temozolomide has been researched along with Nausea in 28 studies
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma." | 9.51 | Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 9.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma." | 9.15 | Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. ( Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A, 2011) |
| "The temozolomide is a promising orally cytotoxic agent used in malignant glioma." | 8.83 | The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006) |
| "Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration." | 7.83 | Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016) |
| "Temozolomide (TMZ) as a concomitant and adjuvant chemotherapy to radiotherapy following maximal surgical resection is the established standard therapy for patients with newly diagnosed high-grade glioma." | 7.81 | Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T, 2015) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 7.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| "To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)." | 7.75 | Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. ( Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009) |
| "In this article, we have compared and analyzed the clinical effects of temozolomide single agent and combined doxorubicin in the treatment of glioma." | 5.51 | Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma. ( Chen, L; Liu, Y, 2022) |
| "CINV remains a distressing side effect experienced by glioma patients receiving multi-day temozolomide therapy, in spite of guideline-based antiemetic therapy with selective serotonin-receptor-antagonists." | 5.34 | Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. ( Affronti, ML; Desjardins, A; Friedman, HS; Healy, P; Herndon, JE; Lipp, ES; McSherry, F; Miller, E; Patel, MP; Peters, KB; Randazzo, DM; Woodring, S, 2020) |
| "Cabozantinib inhibits mesenchymal-epithelial transition factor (MET) and vascular endothelial growth factor receptor 2 (VEGFR2) and has demonstrated activity in patients with recurrent glioblastoma, warranting evaluation of the addition of cabozantinib to radiotherapy (RT) and temozolomide (TMZ) for patients with newly diagnosed high-grade glioma." | 5.22 | Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. ( Chamberlain, MC; Cloughesy, T; Desjardins, A; Glantz, M; Mikkelsen, T; Reardon, DA; Schiff, D; Wen, PY, 2016) |
| "Chemotherapy-induced nausea and vomiting (CINV) is a side effect related to administration of the adjuvant temozolomide (TMZ) in patients affected by glioblastoma." | 5.15 | Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study. ( Bria, E; Corona, M; Fabi, A; Lanzetta, G; Minniti, G; Nardoni, C; Restuccia, MR; Rozzi, A, 2011) |
| "A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
| "The temozolomide is a promising orally cytotoxic agent used in malignant glioma." | 4.83 | The safety of the temozolomide in patients with malignant glioma. ( Dario, A; Tomei, G, 2006) |
| "Concomitant use of temozolomide (TMZ) and radiotherapy, which is the standard therapy for patients with high-grade glioma, involves a unique regimen with multiple-day, long-term administration." | 3.83 | Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Takano, S; Yamamoto, T, 2016) |
| "Temozolomide (TMZ) as a concomitant and adjuvant chemotherapy to radiotherapy following maximal surgical resection is the established standard therapy for patients with newly diagnosed high-grade glioma." | 3.81 | Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study. ( Akutsu, H; Ishikawa, E; Matsuda, M; Matsumura, A; Nakai, K; Onuma, K; Yamamoto, T, 2015) |
| "This study evaluated the toxicity profiles of temozolomide in the treatment of malignant glioma as either concurrent or adjuvant chemotherapy." | 3.80 | Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea. ( Bae, SH; Cho, SY; Kim, CY; Kim, TM; Kim, YH; Kim, YJ; Lee, MM; Lee, SH; Park, CK; Park, MJ, 2014) |
| " The observed adverse effects of temozolomide included nausea, vomiting, headache, constipation, mild marrow suppression, and decreased activity; none of them was severe enough to discontinue the treatment." | 3.75 | Efficacy of temozolomide for recurrent embryonal brain tumors in children. ( Chang, KP; Hsu, TR; Wang, CH; Wong, TT, 2009) |
| "To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)." | 3.75 | Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma. ( Dinter, DJ; Hohenberger, P; Jakob, J; Ströbel, P; Wenz, F, 2009) |
| " Additional trials are needed to better define the optimal dosing in such patients." | 2.77 | A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ( Chow, W; Chung, V; Cristea, M; Frankel, P; Koehler, S; Leong, L; Lim, D; Martel, C; Morgan, R; Portnow, J; Reckamp, K; Shibata, S; Synold, TW; Twardowski, P, 2012) |
| "Ratio of log-transformed means (intravenous:oral) of area under the concentration-time curve and maximum concentration of drug after dosing for temozolomide and 5-(3-methyltriazen-1-yl)imidazole-4-carboxamide (MTIC) met exposure equivalence criteria (90% confidence interval = 0." | 2.75 | Evaluation of the exposure equivalence of oral versus intravenous temozolomide. ( Abutarif, MA; Cantillon, M; Cutler, D; Diez, BD; Kantesaria, B; Ottaviano, FH; Pallotta, MG; Schwarz, M; Statkevich, P; Xuan, F; Zhu, Y, 2010) |
| "Primary tumor sites included breast cancer (n=15), lung cancer (n=12) and other (n=5)." | 2.71 | Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study. ( Aravantinos, G; Bafaloukos, D; Bamias, A; Carina, M; Christodoulou, C; Klouvas, G; Linardou, H; Skarlos, D, 2005) |
| " Plasma samples were obtained on days 1 and 2 to evaluate the pharmacokinetic parameters of TMZ alone and in combination with CDDP." | 2.69 | A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. ( Agarwala, SS; Baker, SD; Barrington, R; Britten, CD; Diab, SG; Eckardt, JR; Eckhardt, SG; Fraass, U; Hammond, LA; Johnson, T; Rowinsky, EK; Statkevich, P; Villalona-Calero, M; Von Hoff, DD, 1999) |
| "Temozolomide (TMZ) has demonstrated clinical antitumor activity." | 2.45 | The safety of temozolomide in the treatment of malignancies. ( Hwu, WJ; Patel, SP; Trinh, VA, 2009) |
| "Nimotuzumab in combination with chemotherapy has moderate activity in patients with malignant gliomas and the toxicities are well tolerable, therefore, worth further investigation." | 1.37 | [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas]. ( Chen, ZP; Jiang, XB; Mu, YG; Sai, K; Shen, D; Yang, QY; Zhang, XH, 2011) |
| "Temozolomide was administered at a dose of 200 mg/m(2) daily for 5 days, in a 4-week cycle." | 1.34 | Temozolomide in pediatric low-grade glioma. ( Ashley, DM; Coleman, LT; Downie, PA; Heath, JA; Khaw, SL, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.57) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 10 (35.71) | 29.6817 |
| 2010's | 12 (42.86) | 24.3611 |
| 2020's | 4 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 1 |
| Chen, L | 1 |
| Patel, MP | 2 |
| Woodring, S | 1 |
| Randazzo, DM | 1 |
| Friedman, HS | 1 |
| Desjardins, A | 2 |
| Healy, P | 1 |
| Herndon, JE | 2 |
| McSherry, F | 1 |
| Lipp, ES | 1 |
| Miller, E | 1 |
| Peters, KB | 1 |
| Affronti, ML | 2 |
| Morio, K | 1 |
| Watanabe, J | 1 |
| Tsujimoto, Y | 1 |
| Wang, HW | 1 |
| Xu, ZK | 1 |
| Song, Y | 1 |
| Liu, YG | 1 |
| Calegari, MA | 1 |
| Inno, A | 1 |
| Monterisi, S | 1 |
| Orlandi, A | 1 |
| Santini, D | 1 |
| Basso, M | 1 |
| Cassano, A | 1 |
| Martini, M | 1 |
| Cenci, T | 1 |
| de Pascalis, I | 1 |
| Camarda, F | 1 |
| Barbaro, B | 1 |
| Larocca, LM | 1 |
| Gori, S | 1 |
| Tonini, G | 1 |
| Barone, C | 1 |
| Yeo, KK | 1 |
| Puscasiu, E | 1 |
| Keating, RF | 1 |
| Rood, BR | 1 |
| Bae, SH | 1 |
| Park, MJ | 1 |
| Lee, MM | 1 |
| Kim, TM | 1 |
| Lee, SH | 1 |
| Cho, SY | 1 |
| Kim, YH | 1 |
| Kim, YJ | 1 |
| Park, CK | 2 |
| Kim, CY | 1 |
| Matsuda, M | 2 |
| Yamamoto, T | 2 |
| Ishikawa, E | 2 |
| Nakai, K | 1 |
| Akutsu, H | 2 |
| Onuma, K | 1 |
| Matsumura, A | 2 |
| Schiff, D | 1 |
| Cloughesy, T | 1 |
| Mikkelsen, T | 1 |
| Glantz, M | 1 |
| Chamberlain, MC | 1 |
| Reardon, DA | 1 |
| Wen, PY | 1 |
| Jeong, JH | 1 |
| Hong, YS | 1 |
| Park, Y | 1 |
| Kim, J | 1 |
| Kim, JE | 1 |
| Kim, KP | 1 |
| Kim, SY | 1 |
| Park, JH | 1 |
| Kim, JH | 1 |
| Park, IJ | 1 |
| Lim, SB | 1 |
| Yu, CS | 1 |
| Kim, JC | 1 |
| Kim, TW | 1 |
| Takano, S | 1 |
| Dario, A | 1 |
| Tomei, G | 1 |
| Wang, CH | 1 |
| Hsu, TR | 1 |
| Wong, TT | 1 |
| Chang, KP | 1 |
| Zwinkels, H | 1 |
| Roon, K | 1 |
| Jeurissen, FJ | 1 |
| Taphoorn, MJ | 1 |
| Hop, WC | 1 |
| Vecht, CJ | 1 |
| Jakob, J | 1 |
| Wenz, F | 1 |
| Dinter, DJ | 1 |
| Ströbel, P | 1 |
| Hohenberger, P | 1 |
| Trinh, VA | 1 |
| Patel, SP | 1 |
| Hwu, WJ | 1 |
| Diez, BD | 1 |
| Statkevich, P | 2 |
| Zhu, Y | 1 |
| Abutarif, MA | 1 |
| Xuan, F | 1 |
| Kantesaria, B | 1 |
| Cutler, D | 1 |
| Cantillon, M | 1 |
| Schwarz, M | 1 |
| Pallotta, MG | 1 |
| Ottaviano, FH | 1 |
| Rozzi, A | 1 |
| Nardoni, C | 1 |
| Corona, M | 1 |
| Restuccia, MR | 1 |
| Fabi, A | 1 |
| Bria, E | 1 |
| Minniti, G | 1 |
| Lanzetta, G | 1 |
| Yang, QY | 1 |
| Shen, D | 1 |
| Sai, K | 2 |
| Mu, YG | 2 |
| Jiang, XB | 1 |
| Zhang, XH | 2 |
| Chen, ZP | 2 |
| Portnow, J | 1 |
| Frankel, P | 1 |
| Koehler, S | 1 |
| Twardowski, P | 1 |
| Shibata, S | 1 |
| Martel, C | 1 |
| Morgan, R | 1 |
| Cristea, M | 1 |
| Chow, W | 1 |
| Lim, D | 1 |
| Chung, V | 1 |
| Reckamp, K | 1 |
| Leong, L | 1 |
| Synold, TW | 1 |
| Christodoulou, C | 1 |
| Bafaloukos, D | 1 |
| Linardou, H | 1 |
| Aravantinos, G | 1 |
| Bamias, A | 1 |
| Carina, M | 1 |
| Klouvas, G | 1 |
| Skarlos, D | 1 |
| Yang, SH | 1 |
| Kim, MK | 1 |
| Lee, TK | 1 |
| Lee, KS | 1 |
| Jeun, SS | 1 |
| Kang, JK | 1 |
| Kim, MC | 1 |
| Hong, YK | 1 |
| Rivera, E | 1 |
| Meyers, C | 1 |
| Groves, M | 1 |
| Valero, V | 1 |
| Francis, D | 1 |
| Arun, B | 1 |
| Broglio, K | 1 |
| Yin, G | 1 |
| Hortobagyi, GN | 1 |
| Buchholz, T | 1 |
| Zhang, JP | 1 |
| Shi, HL | 1 |
| Yue, WY | 1 |
| Khaw, SL | 1 |
| Coleman, LT | 1 |
| Downie, PA | 1 |
| Heath, JA | 1 |
| Ashley, DM | 1 |
| Britten, CD | 1 |
| Rowinsky, EK | 1 |
| Baker, SD | 1 |
| Agarwala, SS | 1 |
| Eckardt, JR | 1 |
| Barrington, R | 1 |
| Diab, SG | 1 |
| Hammond, LA | 1 |
| Johnson, T | 1 |
| Villalona-Calero, M | 1 |
| Fraass, U | 1 |
| Von Hoff, DD | 1 |
| Eckhardt, SG | 1 |
| Wilman, DE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621] | Phase 2 | 135 participants (Actual) | Interventional | 2019-03-25 | Completed | ||
| Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326] | Phase 2 | 21 participants (Anticipated) | Interventional | 2021-12-01 | Recruiting | ||
| Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347] | Phase 1 | 18 participants (Anticipated) | Interventional | 2021-01-01 | Recruiting | ||
| Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975] | Phase 2 | 35 participants (Anticipated) | Interventional | 2022-05-02 | Recruiting | ||
| Preoperative Chemoradiation With Capecitabine Plus Temozolomide in Patients With Locally Advanced Resectable Rectal Cancer: Phase I Study[NCT01781403] | Phase 1 | 22 participants (Actual) | Interventional | 2013-05-10 | Completed | ||
| A Phase I Study of Bortezomib and Temozolomide in Patients With Refractory Solid Tumors[NCT00544284] | Phase 1 | 25 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD is defined as the maximum dose level in the doses of temozolomide tested with capecitabine and radiation in which the incidence proportion of DLT exceeds 30%. (NCT01781403)
Timeframe: 5-6 weeks during study treatment
| Intervention | mg/m^2 (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 0 |
| Dose Level 3/Recommended Dose | 0 |
"Pathologic responses and stages were classified according to Dworak's classification and the 7th edition of the American Joint Committee on Cancer staging system, respectively.~The pathologic complete response (pCR) was defined as the total regression of the primary tumor regardless of regional lymph nodal status (ypT0), with residual fibrotic mass or acellular mucin pools only, thus without detectable tumor cells." (NCT01781403)
Timeframe: at the time of surgery (6-8 weeks after study treatment)
| Intervention | participants (Number) |
|---|---|
| Unmethylated MGMT | 1 |
| Hypermethylated MGMT | 6 |
RD will be defined as one level below the MTD. (NCT01781403)
Timeframe: 5-6 weeks after CRT
| Intervention | mg/m^2 (Number) |
|---|---|
| Dose Level 1 | 0 |
| Dose Level 2 | 0 |
| Dose Level 3/Recommended Dose | 75 |
"Toxicity will be monitored and recorded every week during study treatment (5 or 6 weeks) as following according to the NCI-CTCAE version 4.0~An interval history and physical examination with particular attention to drug-induced side effects along with documentation of the patient's weight and performance status will be performed on each visit.~CBC with differential count, blood chemistry including calcium, phosphorus, glucose, BUN, creatinine, total protein, albumin, AST, ALT, alkaline phosphatase, total bilirubin, and electrolyte will be performed before next planned treatment.~All relevant information regarding drug dosage, laboratory examinations, and treatment-related toxicities must be recorded before each treatment is given.~Summaries of the frequency and severity of adverse effects are based on the worst episodes recorded." (NCT01781403)
Timeframe: 5-6 weeks during study treatment
| Intervention | events (Number) | |||
|---|---|---|---|---|
| Any grade 1 adverse event | Any grade 2 adverse event | Any grade 3 adverse event | Any grade 4 adverse event | |
| Dose Level 1 | 6 | 2 | 1 | 0 |
| Dose Level 2 | 8 | 2 | 0 | 0 |
| Dose Level 3/Recommended Dose | 60 | 17 | 3 | 0 |
2 reviews available for temozolomide and Nausea
| Article | Year |
|---|---|
The safety of the temozolomide in patients with malignant glioma.
Topics: Adult; Antineoplastic Agents, Alkylating; Child; Clinical Trials as Topic; Dacarbazine; Drug Interac | 2006 |
The safety of temozolomide in the treatment of malignancies.
Topics: Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; | 2009 |
12 trials available for temozolomide and Nausea
| Article | Year |
|---|---|
Comparison of Clinical Effects of Temozolomide Single Agent and Combined Doxorubicin in the Treatment of Glioma.
Topics: Doxorubicin; Glioma; Humans; Nausea; Temozolomide; Thrombocytopenia; Treatment Outcome; Vomiting | 2022 |
Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Brain Neoplasms; Female; Glioma; Humans | 2020 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
A phase 2 study of temozolomide in pretreated metastatic colorectal cancer with MGMT promoter methylation.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Dacarbazin | 2017 |
Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antineoplastic Combined Chemotherapy Protocols; Asparta | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Phase 1 Study of Preoperative Chemoradiation Therapy With Temozolomide and Capecitabine in Patients With Locally Advanced Rectal Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dacarb | 2016 |
Evaluation of the exposure equivalence of oral versus intravenous temozolomide.
Topics: Administration, Oral; Adult; Anemia; Antineoplastic Agents, Alkylating; Area Under Curve; Central Ne | 2010 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in glioblastoma patients treated with temozolomide: a phase II study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Combined Modali | 2011 |
A phase I study of bortezomib and temozolomide in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Are | 2012 |
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study.
Topics: Adult; Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brea | 2005 |
Temozolomide chemotherapy in patients with recurrent malignant gliomas.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Drug Administra | 1999 |
14 other studies available for temozolomide and Nausea
| Article | Year |
|---|---|
Letter referencing "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting in glioma patients receiving adjuvant temozolomide".
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Response to the letter to the Editor concerning manuscript entitled, "Randomized open-label phase II trial of 5-day aprepitant plus ondansetron compared to ondansetron alone in the prevention of chemotherapy-induced nausea-vomiting (CINV) in glioma patien
Topics: Antineoplastic Agents; Aprepitant; Glioma; Humans; Nausea; Ondansetron; Temozolomide; Vomiting | 2020 |
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Asian People; Brain Neoplasms; China; Dacarbazine; D | 2017 |
Durable response of intracranial cellular hemangioma to bevacizumab and temozolomide.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brai | 2013 |
Toxicity profile of temozolomide in the treatment of 300 malignant glioma patients in Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents, Alkylating; Brain Neopl | 2014 |
Profile Analysis of Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Chemoradiotherapy; Dacarbazine; Female; | 2015 |
Combination of Palonosetron, Aprepitant, and Dexamethasone Effectively Controls Chemotherapy-induced Nausea and Vomiting in Patients Treated with Concomitant Temozolomide and Radiotherapy: Results of a Prospective Study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Aprepitant; Brain Neoplasms; Dacarbazin | 2016 |
Efficacy of temozolomide for recurrent embryonal brain tumors in children.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; D | 2009 |
Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Topics: Analysis of Variance; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chi-Square Distribution; D | 2009 |
Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Combined Modality Therapy; Dacarb | 2009 |
[Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Alkylating; Antineoplas | 2011 |
[Individualized chemotherapy based on drug sensitivity and resistance assay and MGMT protein expression for patients with malignant glioma--analysis of 42 cases].
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chi | 2006 |
Temozolomide in pediatric low-grade glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Carboplati | 2007 |
Prodrugs in cancer chemotherapy.
Topics: Altretamine; Aniline Mustard; Animals; Antineoplastic Agents; Azo Compounds; Biotransformation; Chem | 1986 |